Almac Group Invests in NMR Equipment to Enhance Existing Analytical Services Capability
July 16, 2018
Craigavon, N.I., 16 July 2018 – Almac Group, the global contract development and manufacturing organisation, has announced a £375,000 investment in additional NMR instrumentation at its global Headquarters, Craigavon, UK.
As part of Almac Sciences’ state-of-the-art cGMP facility, enhanced NMR services will be offered to help deliver comprehensive solutions supporting drug substance (API) and drug product development programs from early phase to commercialisation. These services include advanced characterisation and purity assessment abilities in line with regulatory requirements. This investment boosts the existing well-established Almac NMR testing service already available to clients.
The new 500MHz NMR instrument setup at Almac incorporates Bruker’s cutting-edge Avance Neo platform, in addition to a Prodigy Cryoprobe all within a temperature controlled environment. This provides greater flexibility, higher sensitivity and resolution. The capability to analyse nuclei from 15N to 31P, in addition to a wide range of 2D and quantitative NMR experiments, now allows Almac to increase its NMR service offering.
Almac’s dedicated NMR team has worked with many pharmaceutical companies providing novel solutions to their scientific problems, and now, with analysis running up to ten times faster, the increased through-put and capacity will increase efficiency and turnaround times. In addition, the latest software includes additional processing capabilities and provides superior data integrity controls which will ensure increasing regulatory compliance needs are met.
Dr John Malone, Analytical Manager, Almac Sciences welcomed this enhanced investment “The latest NMR technology installation in our cGMP lab allows increased flexibility and capacity enabling us to better serve our clients.”
“Almac’s continual investment to increase service capacity and ensure full regulatory compliance enables our clients to progress their projects more efficiently through the drug development cycle.” added Dr John Robson, VP Quality Operations, Almac Sciences.